Research programme: alpha-synuclein-targeted diagnostics and therapeutics - AC ImmuneAlternative Names: Alpha-synuclein-PET based diagnostics and therapeutics - AC Immune
Latest Information Update: 22 May 2015
At a glance
- Originator AC Immune
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Parkinson's disease